PARIS, France and TARRYTOWN, NY, USA I May 30, 2025 I The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic ...

SEOUL, South Korea I May 29, 2025 I Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development program for a ...

SYDNEY, Australia I May 29, 2025 I Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - ...

EMERYVILLE, CA, USA I May 29, 2025 I Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company ...

Pharmacokinetics: The pharmacokinetic profile of DF-003 was largely dose proportional and the data support additional clinical trials as a once-daily, orally administered drug.

First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion ...

IVMED-85 is a non-atropine daily eye drop intended to treat pediatric myopia by strengthening scleral and corneal collagen crosslinking through LOX* activation ...

AUTX-703 is a novel, first-in-class, orally available KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data ...

BRANFORD, CT, USA I May 28, 2025 I Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...

(“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research ...

SHENZHEN, China I May 28, 2025 I On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved ...